Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They currently have a $128.00 target price on the biotechnology company's stock. Cantor Fitzgerald's price target would indicate a potential downside of 2.01% from the company's current price.

Several other equities research analysts have also recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a research note on Monday, March 4th. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an "outperform" rating in a research note on Thursday, February 29th. Needham & Company LLC restated a "buy" rating and set a $166.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Barclays upped their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an "overweight" rating in a research report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $156.60.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.27 during midday trading on Thursday, hitting $130.63. The company's stock had a trading volume of 2,230,575 shares, compared to its average volume of 1,015,639. The business's 50 day simple moving average is $125.77 and its 200 day simple moving average is $110.56. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The company has a market cap of $12.35 billion, a P/E ratio of -22.03 and a beta of 0.95. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company's revenue for the quarter was up 63.1% on a year-over-year basis. During the same period last year, the firm posted ($1.44) earnings per share. On average, analysts forecast that Sarepta Therapeutics will post 2.13 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company's stock, valued at $923,941.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company's stock, valued at $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 1,200 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares of the company's stock, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock valued at $2,739,419 over the last 90 days. 7.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Nordea Investment Management AB lifted its stake in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company's stock valued at $8,004,000 after buying an additional 33,711 shares during the last quarter. Connecticut Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at $261,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Sarepta Therapeutics by 111.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company's stock valued at $12,131,000 after purchasing an additional 47,895 shares during the period. Van ECK Associates Corp increased its holdings in shares of Sarepta Therapeutics by 5.3% during the first quarter. Van ECK Associates Corp now owns 86,329 shares of the biotechnology company's stock valued at $11,176,000 after purchasing an additional 4,374 shares during the period. Finally, Naples Global Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at $259,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.